New research suggests that people who discontinue blockbuster GLP-1 drugs like semaglutide or tirzepatide may regain lost weight much more quickly than those who halt conventional lifestyle regimens.
Findings released in a leading medical journal points out that while overweight people can lose a large proportion of their total mass while using the jabs, the mass returns at an average rate of nearly a kilo each month upon discontinuation.
"People purchasing such medications must be informed of the danger of rapid weight regain when the therapy ends," cautioned researcher Dr. Susan Jebb.
This pace of regain implies a reversion to original mass in about 18 months.
Comparing Approaches
The analysis, which reviewed 37 of studies involving thousands of patients, contrasted the outcomes of GLP-1 agonists with older methods.
The team note that people who lose weight through diet and exercise typically see a slower creep back—perhaps 100 grams monthly—post-intervention.
Understanding the Rapid Rebound
Doctors propose the mode of action of the jabs explains the heightened weight return.
GLP-1 drugs copy a natural hormone called GLP-1, which controls appetite.
"Artificially providing the hormone levels far above than the body's typical production could lead to the body to produce less of its endogenous hormone, and could lessen sensitivity to its actions," noted Dr. Adam Collins, a dietetics specialist.
"Stopping of this GLP-1 'fix' means appetite is unsuppressed, making overeating far more likely."
An Ongoing Issue?
Medical guidelines suggest the injections for people with obesity-related medical conditions, accompanied by recommended lifestyle changes.
Many experts argue that, given the significant potential of relapse, the treatment should be considered life-long.
This view is supported by pharmaceutical companies, who note that the findings "highlight the persistent character of obesity," akin to managing conditions like hypertension.
User Experiences
Users who have discontinued the jabs describe a sudden return of appetite.
"I experienced something activating and you become extremely hungry," described an individual.
The struggle is compounded if patients have not developed sustainable lifestyle or habit changes during therapy.
Widespread Adoption
Survey data show that a significant number of people in the UK have tried these injections in the past year, with demand being substantial.
- Use is higher among women compared to men.
- The middle-aged age group shows the greatest level of interest.
- A large proportion obtain the drugs through private prescriptions rather than public health services.
In conclusion, researchers emphasize that while the jabs are potent tools for weight loss, they are not a permanent solution and lasting health benefits hinges on ongoing behavioural support.
